<DOC>
	<DOCNO>NCT02919774</DOCNO>
	<brief_summary>The study evaluate effect mGluR2/3 partial agonist LY2140023 ( Pomaglumetad Methionil , `` POMA '' ) select dose ketamine-stimulated glutamate release prefrontal cortex measure pharmacoBOLD fMRI ( also term rest BOLD fMRI ) .</brief_summary>
	<brief_title>Pomaglumetad Effects Glutamate Biomarkers</brief_title>
	<detailed_description>This study evaluate effect POMA select dos ketamine-stimulated glutamate increase prefrontal cortex hypothesize simulate synaptic dysregulation occur endogenously pathogenesis schizophrenia . The purpose : 1 ) determine whether low dose ( 40 mg BID ) utilize recent ( fail ) clinical trial sufficient engage primary target 2 ) whether high ( 160 mg BID ) dose , represent maximum tolerate dose POMA , engage target great degree . This study validate pharmacoBOLD biomarker mGluR2/3 target engagement , permit future use glutamatergic drug development .</detailed_description>
	<criteria>Medically healthy Capable understand study procedure able provide inform consent Men woman must agree use reliable method birth control study . Women postmenopausal otherwise childbearing potential also eligible Current past Axis I psychiatric history Positive urine toxicology History recreational ketamine use , recreational PCP use , adverse reaction ketamine . Subjects participate prior research ketamine study eligible . Subjects infusion frequently biweekly , 1/month average , therefore subject enter study need wait one month single infusion 6 week two closely spaced infusion . History firstdegree relative schizophrenia History violence Presence positive history significant medical illness Presence positive history neurological illness disease/procedure/accident/intervention association significant injury malfunction central nervous system ( CNS ) history significant head injury Pregnancy breast feeding Metal implant , pacemaker , metal paramagnetic object contain within body Medicinal patch , unless remove prior MRI scan Currently take psychotropic medication , include antidepressant medication , benzodiazepine , antipsychotic medication , mood stabilizer , antiepileptic medication stimulant . Claustrophobia Suicidal ideation intent plan 6 month prior screen Weight &gt; 86.95 kg ( 191.2 lb ) Subthreshold pharmacoBOLD response screen ketamine infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>